Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 604 participants.
Also called NCT02855684
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 604 participants
- Sponsor
- Registry
-
NCT02855684
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02855684. Randomized; no masking; primary purpose treatment. Start 2016-08-24 (registry gives no type); primary completion 2018-08-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
- Acronym
- EDITION AP
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine (U300)
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Non-insulin antihyperglycemic drugs
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02855684- Content hash
b0ebbe63c8a89b3fa98a16790842f9d4b1cc1023f28e8473a69086405c0ae530